Healthcare Industry News: diabetic foot ulcers
News Release - July 10, 2012
Derma Sciences Receives CE Mark for MEDIHONEY(R) HCSProduct to be launched in January 2013
PRINCETON, N.J.--(Healthcare Sales & Marketing Network)--Derma Sciences, Inc. (DSCI), a medical device and pharmaceutical company focused on advanced wound care, announces receipt of the CE Mark for the Company’s patented MEDIHONEY® HCS (hydrogel colloidal sheet) dressings. With this determination the entire current line of MEDIHONEY products has CE marking.
"We will launch commercial sales of MEDIHONEY HCS dressings in Europe in January 2013,” said Edward J. Quilty, chief executive officer of Derma Sciences. “This will be a significant launch as it will help bring our products more deeply into the acute care segment and, for the first time, into the burn care segment. Currently approximately 20% of MEDIHONEY product sales are from Europe and we look forward to further penetration of that market with our advanced wound care products.”
Derma Sciences’ HCS dressings (XTRASORB® and now MEDIHONEY) are differentiated in the market in that they utilize super-absorbing hydrogels not only to provide moisture to dry wounds, but also to absorb moderate to even heavy amounts of wound fluid. This creates extremely versatile dressings that can be used on multiple wound indications and conditions, are easy to use and can be left on wounds for extended periods of time, helping to reduce the overall cost of care. Notably, these novel super-absorbent hydrogels have been shown to lock damaging wound proteases into the dressings, which helps to maintain a more optimal wound environment for healing.
MEDIHONEY is a unique line of patented wound care dressings containing Active Leptospermum Honey from New Zealand, which possess unique qualities that make them ideal for the management of chronic and acute wounds and burns. With a strong and growing base of peer-reviewed evidence including several large-scale randomized controlled studies, MEDIHONEY dressings have shown to be effective for debridement and helping to advance hard-to-heal stalled wounds through the healing process.
About Derma Sciences, Inc.
Derma Sciences is a medical technology company focused on three segments of the wound care marketplace: pharmaceutical wound care products, advanced wound care dressings and traditional dressings. Derma Sciences has successfully completed the Phase 2 clinical trial in diabetic foot ulcer healing with DSC127, an investigational pharmaceutical drug under development for accelerated wound healing and scar reduction, and is preparing to begin Phase 3 clinical trials. Its MEDIHONEY® product is the leading brand of honey-based dressings for the management of wounds and burns. The product has been shown to be effective in a variety of indications, and was the focus of a positive large-scale, randomized controlled trial involving 108 subjects with leg ulcers. Other novel products introduced into the $14 billion global wound care market include XTRASORB® for better management of wound exudate, BIOGUARD® for infection prevention and TCC-EZ™, a gold-standard treatment for diabetic foot ulcers. For more information please visit www.dermasciences.com.
Statements contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release or that are otherwise made by or on behalf of the Company. Factors that may affect the Company's results include, but are not limited to, product demand, market acceptance, impact of competitive products and prices, product development, including clinical trial results, completion of an acquisition, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include but are not limited to, those discussed in the Company's filings with the U.S. Securities and Exchange Commission.
Source: Derma Sciences
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.